{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:12:47Z","timestamp":1761520367442,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clcc.2022.05.004","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T12:55:59Z","timestamp":1653310559000},"page":"252-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA\/PTEN-Wild Type) Metastatic Colorectal Cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Jeremy","family":"Chuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sierra Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clcc.2022.05.004_bib0001","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.clcc.2022.05.004_bib0002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/COC.0b013e3181fe41ed","article-title":"Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005","volume":"34","author":"Cheng","year":"2011","journal-title":"Am J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clcc.2022.05.004_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2014.59.7633","article-title":"Metastatic colorectal cancer: current state and future directions","volume":"33","author":"Fakih","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clcc.2022.05.004_bib0004","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"8 Supplement","key":"10.1016\/j.clcc.2022.05.004_bib0005","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1158\/1538-7445.AM10-1637","article-title":"Abstract 1637: The MEK\/Erk pathway is required for PC3 cell survival following FdUMP[10]treatment","volume":"70","author":"Gomes","year":"2010","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.clcc.2022.05.004_bib0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bjc.6601048","article-title":"Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells","volume":"89","author":"Jin","year":"2003","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.clcc.2022.05.004_bib0007","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/CAD.0000000000000218","article-title":"Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases","volume":"26","author":"Yan","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clcc.2022.05.004_bib0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1741-7015-7-41","article-title":"Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study","volume":"7","author":"Zhang","year":"2009","journal-title":"BMC Med"},{"issue":"23","key":"10.1016\/j.clcc.2022.05.004_bib0009","doi-asserted-by":"crossref","first-page":"34322","DOI":"10.18632\/oncotarget.9107","article-title":"MEK5\/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism","volume":"7","author":"Pereira","year":"2016","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.clcc.2022.05.004_bib0010","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-11-0358","article-title":"Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition","volume":"17","author":"Urick","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clcc.2022.05.004_bib0011","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cas.12139","article-title":"Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells","volume":"104","author":"Watanabe","year":"2013","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.clcc.2022.05.004_bib0012","first-page":"1695","article-title":"Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment","volume":"38","author":"Yang","year":"2011","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2022.05.004_bib0013","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","article-title":"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212","volume":"11","author":"Jing","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.clcc.2022.05.004_bib0014","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-09-1577","article-title":"Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)","volume":"70","author":"Dry","year":"2010","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.clcc.2022.05.004_bib0015","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers","volume":"69","author":"Wee","year":"2009","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.clcc.2022.05.004_bib0016","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1158\/1078-0432.CCR-11-2683","article-title":"Inhibition of MEK and PI3K\/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas","volume":"18","author":"Migliardi","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.clcc.2022.05.004_bib0017","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1158\/1535-7163.MCT-15-0223","article-title":"Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer","volume":"14","author":"Raja","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"45","key":"10.1016\/j.clcc.2022.05.004_bib0018","doi-asserted-by":"crossref","first-page":"79750","DOI":"10.18632\/oncotarget.19336","article-title":"A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy","volume":"8","author":"Cho","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.clcc.2022.05.004_bib0019","first-page":"2831","article-title":"MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines","volume":"37","author":"Gong","year":"2017","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.clcc.2022.05.004_bib0020","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41467-019-09898-0","article-title":"MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer","volume":"10","author":"Zhan","year":"2019","journal-title":"Nature Communications"},{"issue":"9","key":"10.1016\/j.clcc.2022.05.004_bib0021","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41416-019-0434-5","article-title":"Targeting \u03b2-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations","volume":"120","author":"Moon","year":"2019","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1016\/j.clcc.2022.05.004_bib0022","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","article-title":"MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors","volume":"72","author":"Turke","year":"2012","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.clcc.2022.05.004_bib0023","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3390\/cancers11121866","article-title":"Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells","volume":"11","author":"Tsubaki","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.clcc.2022.05.004_bib0024","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.clcc.2022.05.004_bib0025","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2217\/fon-2020-1238","article-title":"Trifluridine\/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design","volume":"17","author":"Tabernero","year":"2021","journal-title":"Future Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2022.05.004_bib0026","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1200\/JCO.2021.39.15_suppl.3566","article-title":"RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II\/III trial of the German AIO (AIO-KRK-0316)","volume":"39","author":"Kasper","year":"2021","journal-title":"J Clinic Oncol"},{"issue":"4_suppl","key":"10.1016\/j.clcc.2022.05.004_bib0027","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2019.37.4_suppl.630","article-title":"A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC)","volume":"37","author":"Cecchini","year":"2019","journal-title":"J Clinic Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002822000640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002822000640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:08:38Z","timestamp":1761520118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002822000640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1533002822000640"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2022.05.004","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA\/PTEN-Wild Type) Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2022.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}